美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

2倍做多NVO ETF-Defiance

10.51

0.0000

盘后：10.580.0700+0.67%19:58 EDT

成交量：108.41万

成交额：1,149.88万

市值：3,560.89万

市盈率：- -

高：11.02

开：10.95

低：10.47

收：10.51

52周最高：72.16

52周最低：9.23

股本：338.81万

流通股本：338.81万

量比：1.38

换手率：32.00%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

减重巨头决战线上，“可及性”成关键赛点

“减肥神药”，价格要崩了

减重版司美格鲁肽“上新”，更高剂量Wegovy已在美国获批

21世纪经济报道

凌激副部长兼国际贸易谈判副代表会见丹麦诺和诺德公司执行副总裁林意明

南方财经网

诺和诺德(NVO.US)拟在日本拓展减肥药市场，“曲线入市“瞄准自费患者蓝海

诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道

诺和诺德(NVO)股票3月18日盘中下跌3.12%：投资者必看的核心信息

TradingKey中文

Structure肥胖药物研究结果直追诺和诺德与礼来

反弹50%只是开始？深度复盘HIMS与药王的“世纪大和解”

Hims & Hers Health(HIMS)盘前涨8% 日前与诺和诺德建立新的合作伙伴关系

$365亿新“药王”诞生！减肥“神药”领跑，“自免”新星高涨50%，潜力市场冲刺100亿大关

FDA 连发多份 CRL，开年大批新药上市申请已遭拒

FDA震怒？！诺和诺德瞒报死亡、中风与自杀倾向，司美、利拉鲁肽遭警告

诺和诺德遇 FDA 监管提醒，GLP-1 药物不良事件报告待完善

细胞基因研究圈

诺和诺德旗下“问题”工厂，又一家药企遭殃

生物制药小编

诺和诺德(NVO)股票3月10日盘中下跌3.13%：原因全解读

TradingKey中文

美股异动丨诺和诺德跌3.3%，因未报告旗下减肥药的所有疑似副作用接获FDA警告信

Hims & Hers与诺和诺德达成和解

环球市场播报

跨国药企2025年成绩单：“药王”易主，创新资产交易创新高

21世纪经济报道

Hims & Hers Health盘前续涨超2%，诺和诺德旗下明星减肥药将登陆平台

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NVOX/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":10.51,"timestamp":1775851200000,"preClose":10.51,"halted":0,"volume":1084090,"hourTrading":{"tag":"盘后","latestPrice":10.58,"preClose":10.51,"latestTime":"19:58 EDT","volume":3068,"amount":32348.13,"timestamp":1775865508232,"change":0.07,"changeRate":0.00666,"amplitude":0.00666},"delay":0,"changeRate":0,"floatShares":3388101,"shares":3388101,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"04-10 16:00:00 EDT","open":10.95,"high":11.02,"low":10.47,"amount":11498805.492615001,"amplitude":0.052331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":10.51,"sharesOutstanding":4098101,"nav":10.5,"aum":35575060.5,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":10.92,"preClose":10.51,"latestTime":"09:29 EDT","volume":7856,"amount":84525.76784,"timestamp":1775827789858,"change":0.41,"changeRate":0.03901,"amplitude":0.059591},"postHourTrading":{"tag":"盘后","latestPrice":10.58,"preClose":10.51,"latestTime":"19:58 EDT","volume":3068,"amount":32348.13,"timestamp":1775865508232,"change":0.07,"changeRate":0.00666,"amplitude":0.00666},"volumeRatio":1.3783485521067123,"impliedVol":0.862,"impliedVolPercentile":0.502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":3388101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.3783485521067123,"shares":3388101,"dividePrice":0,"high":11.02,"amplitude":0.052331,"preClose":10.51,"low":10.47,"week52Low":9.23,"pbRate":"--","week52High":72.16,"institutionHeld":0,"latestPrice":10.51,"eps":0,"divideRate":0,"volume":1084090,"delay":0,"ttmEps":0,"open":10.95,"prevYearClose":21.89,"prevWeekClose":10.3,"prevMonthClose":10.23,"prevQuarterClose":10.23,"fiveDayClose":10.3,"twentyDayClose":10.49,"sixtyDayClose":29.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622043829","title":"减重巨头决战线上，“可及性”成关键赛点","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043829","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043829?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 10:12","pubTimestamp":1774404748,"startTime":"0","endTime":"0","summary":"火爆全球多年的GLP-1减重药赛道，在2025年迎来了历史性转折点。01巨头攻守战，“可及性”成赛点对于如今的诺和诺德而言，药品可及性已然成为其在GLP-1赛道上仅存的竞争优势。显而易见，CagriSema未能在头对头试验中击败替尔泊肽，这场关键战役的失利，直接导致诺和诺德股价在次日暴跌14.64%。一旦Orforglipron顺利上市，诺和诺德独占的口服GLP-1市场将被打破，其仅存的可及性优势也将岌岌可危，甚至可能彻底失守。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774314534087933025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1093756325.SGD","LLY","BK4585","IE00BZ1G4Q59.USD","NVO","BK4007","LU1093756168.USD","BK4532","BK4588","IE00BKVL7J92.USD","NVOH","LU0154236417.USD","NVOX","BK4599"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621037044","title":"“减肥神药”，价格要崩了","url":"https://stock-news.laohu8.com/highlight/detail?id=2621037044","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621037044?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 11:52","pubTimestamp":1774324357,"startTime":"0","endTime":"0","summary":"文｜首席品牌评论2026年3月20日，一个值得写入中国医药产业史的日子。这一天，司美格鲁肽——这款被冠以“减肥神药”之名的全球药王，在中国的核心化合物专利正式到期。专利悬崖如期而至。悬崖之下，是一群早已架好梯子的药企。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774276430002024993","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE00BZ1G4Q59.USD","NVOH","BK4588","IE00BKVL7J92.USD","NVOX","LU1093756325.SGD","BK4585","LU0154236417.USD","BK4532","BK4007","LU1093756168.USD","NVO","BK4599"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621067907","title":"减重版司美格鲁肽“上新”，更高剂量Wegovy已在美国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067907","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067907?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 20:57","pubTimestamp":1774270620,"startTime":"0","endTime":"0","summary":"诺和诺德近日宣布，美国食品药品监督管理局（FDA）已批准Wegovy?HD（每周一次司美格鲁肽注射液7.2mg），用于降低过多体重并长期维持减重效果。FDA此前已向Wegovy?HD授予“局长国家优先审批券”（CNPV），从而加快了其审批进程，并凸显其在应对关键患者需求及美国国家健康优先事项方面的潜力。该加速批准基于STEPUP试验项目研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233681185257.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233681185257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0942090050.USD","LU2756315318.SGD","LU1236620834.HKD","LU1929549753.HKD","BK4534","LU1989772923.USD","LU0820562030.AUD","IE00BKVL7J92.USD","LU2361044865.SGD","SG9999001440.SGD","IE00B1XK9C88.USD","LU2461242641.AUD","BK4007","LU2756315664.SGD","LU1162221912.USD","LU1551013342.USD","LU0868494617.USD","NVOX","IE00BWXC8680.SGD","BK4581","LU0320765646.SGD","LU1674673428.USD","LU1989772840.SGD","LU2361044949.HKD","LU0823411888.USD","LU1914381329.SGD","LU1674673691.USD","BK4504","LU1778281490.HKD","LU2361045086.USD","BK4533","LU1093756168.USD","LU1069344957.HKD","LU1496350171.SGD","LU1496350502.SGD","LU0868494708.USD","NVOH","HD","LU0820561909.HKD","LU0354030511.USD","LU0238689110.USD","LU0079474960.USD","IE00BSNM7G36.USD","LU0823434740.USD","LU1093756325.SGD","BK4566","LU1551013425.SGD","LU0943347566.SGD","LU0098860793.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621953726","title":"凌激副部长兼国际贸易谈判副代表会见丹麦诺和诺德公司执行副总裁林意明","url":"https://stock-news.laohu8.com/highlight/detail?id=2621953726","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621953726?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 11:20","pubTimestamp":1774236000,"startTime":"0","endTime":"0","summary":"南方财经3月23日电，据商务部消息，3月20日，商务部副部长兼国际贸易谈判副代表凌激会见丹麦诺和诺德公司执行副总裁林意明，双方围绕企业在华经营情况、中国开放发展机遇等议题进行交流。凌激表示，近年来，中国科技创新能力快速提升，医药健康产业规模不断扩大。中国以新质生产力推动经济高质量发展，已成为全球创新策源地。希望诺和诺德持续深耕中国市场，为建设健康中国作出贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233680260164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4007","NVO","IE00BZ1G4Q59.USD","BK4599","IE00BKVL7J92.USD","BK4532","LU1093756325.SGD","BK4585","NVOX","LU0154236417.USD","LU1093756168.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620903249","title":"诺和诺德(NVO.US)拟在日本拓展减肥药市场，“曲线入市“瞄准自费患者蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2620903249","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620903249?lang=zh_cn&edition=fundamental","pubTime":"2026-03-19 18:25","pubTimestamp":1773915956,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德公司正寻求通过瞄准愿意自费使用Wegovy等胰高血糖素样肽-1药物的患者，来扩大肥胖症治疗在日本的可及性。诺和诺德推动自费医疗的举措，反映了整个行业在渗透率不足的市场扩大治疗的更广泛努力。在肥胖症和罕见病疗法的推动下，诺和诺德日本业务部门去年收入增长了5.4%。\"诺和诺德在日本的努力可能沿袭了其在美国建立的直接面向消费者的销售路径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1093756168.USD","BK4007","BK4599","LU0154236417.USD","LU1093756325.SGD","BK4588","NVOH","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVO","BK4532","BK4585","NVOX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620431362","title":"诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2620431362","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620431362?lang=zh_cn&edition=fundamental","pubTime":"2026-03-19 17:07","pubTimestamp":1773911228,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4599","BK4007","NVOH","LU0154236417.USD","BK4532","BK4588","NVO","LU1093756325.SGD","LU1093756168.USD","BK4585","NVOX","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620501842","title":"诺和诺德(NVO)股票3月18日盘中下跌3.12%：投资者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2620501842","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620501842?lang=zh_cn&edition=fundamental","pubTime":"2026-03-18 23:16","pubTimestamp":1773846978,"startTime":"0","endTime":"0","summary":"• FDA警告信指出司美格鲁肽产品存在违规行为。\n• 竞争加剧以及对研发管线的担忧影响了公司前景。\n• 修订后的2026年营收指引预示销售额将出现下滑。","market":"nz","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/Market-Movers/261695175-market-movers-nvo-20260318","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK7104","BK4588","LU0154236417.USD","NVOX","NVO","BK4599","BK4007","BK4532","NVOH","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620476890","title":"Structure肥胖药物研究结果直追诺和诺德与礼来","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620476890?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 23:08","pubTimestamp":1773760090,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0466842654.USD","LU2108987350.USD","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","LU2023251221.USD","LU2361044949.HKD","SG9999014914.USD","LU2456880835.USD","LU0964807845.USD","IE0009355771.USD","LU0061475181.USD","LU0198837287.USD","LU2211815571.USD","LU2168563687.JPY","LU1061106388.HKD","LU2552382058.USD","LU2756315318.SGD","LU1057294990.SGD","LU2168564495.EUR","LU2462157665.USD","LU0266013472.USD","LU0823434740.USD","BK4599","LU1093756168.USD","SG9999013999.USD","LU2471134523.USD","LU0203201768.USD","LU1868837136.USD","LU0672654240.SGD","LU0882574055.USD","LU0417517546.SGD","LU0109391861.USD","LU2237443465.HKD","IE00B4R5TH58.HKD","LU1974910355.USD","LU2746668974.SGD","LU0323591593.USD","LU2087625088.SGD","SG9999014906.USD","SG9999017495.SGD","LU0456855351.SGD","LU2491049909.HKD","LU0109394709.USD","LU2461242641.AUD","IE00BJJMRZ35.SGD","LU0210536198.USD","LU1988902786.USD","LU0158827781.USD","IE0002141913.USD","LU1623119135.USD","LU1127390331.HKD","LU2236285917.USD","LU2237443622.USD","LU0640476718.USD","LU1720051017.SGD","IE00BFSS8Q28.SGD","IE00B1XK9C88.USD","LU2264538146.SGD","LU0786609619.USD","LU0471298777.SGD","LU2028103732.USD","LU2471134952.CNY","LU2168564149.EUR","LU1232071149.USD","ELIS","SGXZ99366536.SGD","SG9999018865.SGD","BK4516","IE00BZ1G4Q59.USD","SG9999014880.SGD","LU2552382132.HKD","SGXZ81514606.USD","LU2417539215.USD","LU0097036916.USD","LU2471134879.HKD","IE0005OL40V9.USD","LU0823416689.USD","LU2063271972.USD","LU0256863811.USD","IE00B7KXQ091.USD","LU0471298694.HKD","SGXZ57979304.SGD","LU1989771016.USD","LU1551013342.USD","IE0004445239.USD","LU0154236417.USD","LU0882574139.USD","LU1868836757.USD","LU2361045086.USD","LU0354030511.USD","LU2237443895.HKD","IE00BFSS7M15.SGD","IE00BK4W5L77.USD","IE00B4JS1V06.HKD","LU2357305700.SGD","LU1868836914.USD","LU2750360641.GBP","GB00BDT5M118.USD","LU1548497426.USD","IE00BKDWB100.SGD","IE00BN29S564.USD","IE00BJJMRY28.SGD","LLYZ","LU1720051108.HKD","LU2089283258.USD","SGXZ31699556.SGD","SG9999015986.USD","LU2265009873.SGD","LU0385154629.USD","LU0683600562.USD","LU1917777945.USD","LU2112291526.USD","LU0238689110.USD","NVOX","LU1868836591.USD","LU2168564222.USD","LU0094547139.USD","IE00BJJMRX11.SGD","LU0106261372.USD","ELIL","BK4532","LU2168564065.EUR","SG9999015952.SGD","BK4534","LU0158827948.USD","LU2237438978.USD","LU2023250504.SGD","LU2491050154.USD","LU2552382215.SGD","LU1035775433.USD","LU1323610961.USD","LU0316494557.USD","IE0001KFT4U8.USD","LU0787776722.HKD","LU2361044865.SGD","SGXZ51526630.SGD","LU0320765992.SGD","BK4533","LU0689472784.USD","LU2602419157.SGD","SG9999014898.SGD","BK4581","LU2089984988.USD","IE00BJT1NW94.SGD","LU2746668461.USD","LU0889565916.HKD","IE0004445015.USD","LU0354030438.USD","LU1267930730.SGD","LU2756315664.SGD","IE00BKVL7J92.USD","SG9999015945.SGD","LU0820561909.HKD","LU1629891620.HKD","LU0432979614.USD","LU1366192091.USD","SG9999015978.USD","LU2111349929.HKD","SG9999018857.SGD","LU1983299246.USD","LU0114720955.EUR","IE00B775H168.HKD","LU1291159041.SGD","LU1551013425.SGD","LU0943347566.SGD","LU2089284900.SGD","LU2360106947.USD","IE00BJLML261.HKD","LU0122379950.USD","LLII","LU1814569148.SGD","LU1064131342.USD","LU0823434583.USD","BK4585","LU2468319806.SGD","LU0256863902.USD","IE00B2B36J28.USD","LU2023250330.USD","LU0079474960.USD","LU1804176565.USD","SG9999001176.USD","LU2324357040.USD","LU0058720904.USD","LU1069344957.HKD","LU0203202063.USD","LU2237443382.USD","LU0225283273.USD","LU1868837300.USD","LU0820562030.AUD","LU1145028129.USD","LU1023059063.AUD","IE00BKPKM429.USD","LU1280957306.USD","LU2471134796.USD","LU0353189680.USD","LU2106854487.HKD","IE00BWXC8680.SGD","LU0006306889.USD","LU1712237335.SGD","BK4588","LU0820561818.USD","LU2213496289.HKD","LU2750360997.AUD","LLYX","LU0289739699.SGD","LU2237443549.SGD","LU2237443978.SGD","LU0234572021.USD","LU2271345857.HKD","BK4007","LU1093756325.SGD","LU0096364046.USD","NVOH","SG9999001176.SGD","LU0320765059.SGD","GPCR","LU0353189763.USD","LU0708995401.HKD","LU2896262040.SGD","LU2491050071.SGD","IE00BK4W5M84.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619019014","title":"反弹50%只是开始？深度复盘HIMS与药王的“世纪大和解”","url":"https://stock-news.laohu8.com/highlight/detail?id=2619019014","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619019014?lang=zh_cn&edition=fundamental","pubTime":"2026-03-13 21:20","pubTimestamp":1773408035,"startTime":"0","endTime":"0","summary":"在狂热中保持一份清醒","market":"hk","thumbnail":"https://img3.gelonghui.com/3c716-ca1a8464-8f16-4866-ab41-c44262ef4bdf.jpg?guru_height=876&guru_width=1605&guru_size=79794","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/3c716-ca1a8464-8f16-4866-ab41-c44262ef4bdf.jpg?guru_height=876&guru_width=1605&guru_size=79794"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4071127","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4588","BK4007","HIMS","NVOH","IE00BZ1G4Q59.USD","BK4599","HIYY","BK4532","HMYY","BK4585","IE00BKVL7J92.USD","HIMY","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","NVOX","BK4196"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618138250","title":"Hims & Hers Health(HIMS)盘前涨8% 日前与诺和诺德建立新的合作伙伴关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138250","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138250?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 18:08","pubTimestamp":1773310089,"startTime":"0","endTime":"0","summary":"金吾财讯 | Hims & Hers Health 盘前涨8%，截至发稿，报27.950美元。消息面上，日前，Hims & Hers Health与诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。但如果医生认为患者有必要使用，该公司仍将销售Wegovy和Ozempic的复配版本。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZTgzYzFjMzMwYjg4MjEzNTY0MzUzNDIy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"297963","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HIMY","HMYY","HIMS","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532","BK4007","LU1093756325.SGD","NVOX","BK4599","LU0154236417.USD","BK4588","LU1093756168.USD","HIMZ","BK4585","NVOH","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618917441","title":"$365亿新“药王”诞生！减肥“神药”领跑，“自免”新星高涨50%，潜力市场冲刺100亿大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917441","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618917441?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 16:25","pubTimestamp":1773217553,"startTime":"0","endTime":"0","summary":"据梳理，TOP1产品销售额、TOP10产品销售额门槛对比2024年均有提升；替尔泊肽全球销售额超365亿美元，首次斩获“药王”宝座，司美格鲁肽以微弱差距排名第二；抗肿瘤赛道大热，帕博利珠单抗、达雷妥尤单抗、纳武利尤单抗成“三足鼎立”之势；自免新星加速崛起，利生奇珠单抗大涨50%；抗凝老将阿哌沙班坚守TOP4，HIV金标准比克恩丙诺稳健增长。全球新“药王”诞生！其中，BMS贡献约144.43亿美元的销售额，辉瑞的销售额约89.61亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163736a6b79845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163736a6b79845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","LU0058720904.USD","LU1917777945.USD","LU2023250843.SGD","LU1057294990.SGD","IE00B1BXHZ80.USD","LU2461242641.AUD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","LU0432979614.USD","LU0006306889.USD","LU0320765489.SGD","LU1116320901.HKD","BK4534","LU0122379950.USD","LU1066053197.SGD","LU0985320562.USD","IE00BLSP4452.SGD","BK4559","LU1069347547.HKD","LU0965508806.USD","LU0106261372.USD","LU0477156953.USD","LU0265550359.USD","LU1093756168.USD","BK4585","ABBV","LU0965509283.SGD","LU1430594728.SGD","LU1037948541.HKD","IE00BJJMRZ35.SGD","LU1941712264.USD","LU0265550946.USD","IE00BZ1G4Q59.USD","SG9999013999.USD","LU2112291526.USD","IE00B2B36J28.USD","LU0070302665.USD","SG9999001176.SGD","LU1934455277.USD","IE0002141913.USD","SG9999002224.SGD","IE000M9KFDE8.USD","LU1037948897.HKD","NVO","SG9999015341.SGD","LU1934455194.USD","LU1934455863.HKD","LU1941712348.USD","LU0130517989.USD","LU2106854487.HKD","SG9999002232.USD","LU2089984988.USD","IE00B4R5TH58.HKD","SG9999001176.USD","LU1162221912.USD","LU1061106388.HKD","IE00BLSP4239.USD","SG9999014542.SGD","NVOX","LU1699723380.USD","SG9999014575.USD","SG9999015358.SGD","IE00BSNM7G36.USD","LU0861579265.USD","MRK","LU0098860793.USD","LU1929549753.HKD","LU1035773651.USD","BK4588","SGXZ57979304.SGD","LU0203345920.USD","LU2361044865.SGD","LU1989772840.SGD","SG9999001440.SGD","BK4550","LLY","LU1066051811.HKD","LU0980610538.SGD","LU1571399168.USD","LU0868494708.USD","LU2361045086.USD","LU0942090050.USD","LU1201861249.SGD","BK4599","LU1989772923.USD","LU1066051225.USD","LU0211331839.USD","BK4516","LU1989771016.USD","LU0965509101.SGD","LU2324357040.USD","BK4532","LU0965509010.AUD","LU1116320737.USD","LU1291159041.SGD","LU2468319806.SGD","IE00BBT3K403.USD","LU0648001328.SGD","LU1585245621.USD","LU1023059063.AUD","LU1983299246.USD","IE0009355771.USD","LU2125154935.USD","BK4533","LU1066051498.USD","LU2023250504.SGD","LU1974910355.USD","LU0208291251.USD","LU0203347892.USD","SG9999014559.SGD","LU1093756325.SGD","LU0234572021.USD","LU0266013472.USD","SG9999014567.USD","IE00BJT1NW94.SGD","NVOH","LU2360032135.SGD","IE00BN8TJ469.HKD","BK4007","LU0130102774.USD","LU0289739699.SGD","LU0868494617.USD","LU2361044949.HKD","LU2125154778.USD","LU0238689110.USD","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618157119?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFMHRM44.USD","BK4007","LU1815336091.USD","REGN","BK4530","BK4585","BK4599","IE00BKVL7J92.USD","BK4588","LU0154236417.USD","LU0029874061.USD","NVO","NVOX","LU0390134368.USD","BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","INCY","LU0757428866.USD","BK4121","NVOH","LU1093756168.USD","AZN","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618153939","title":"FDA震怒？！诺和诺德瞒报死亡、中风与自杀倾向，司美、利拉鲁肽遭警告","url":"https://stock-news.laohu8.com/highlight/detail?id=2618153939","media":"药闻天下","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618153939?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 12:33","pubTimestamp":1773203611,"startTime":"0","endTime":"0","summary":"事实上，这并非FDA的突击制裁，而是一场长达一年、最终崩盘的合规拉锯战。在过去整整一年里，诺和诺德信誓旦旦地向FDA提交了多达7次的整改进度报告。根据FDA的警告信披露，诺和诺德的安全数据库中存在大量令人脊背发凉的“漏报”案例：“患者说无关，我们就取消”：在Argus的1331385号病例中，一名使用利拉鲁肽的患者遭遇了中风导致残疾。诺和诺德斥巨资从Catalent手中收购的印第安纳州布卢明顿工厂，近期同样吃到了FDA的警告信。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311143523954825dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311143523954825dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","NVOX","BK4588","BK4532","NVO","LU1093756168.USD","NVOH","BK4007","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","IE00BKVL7J92.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618399032","title":"诺和诺德遇 FDA 监管提醒，GLP-1 药物不良事件报告待完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2618399032","media":"细胞基因研究圈","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618399032?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 11:58","pubTimestamp":1773201494,"startTime":"0","endTime":"0","summary":"摘要：2026 年 3 月，丹麦药企诺和诺德美国新泽西普兰斯堡总部收到 FDA 正式警告信，核心问题集中在上市后不良药物事件 报告体系的合规性上。涉事产品包含司美格鲁肽等王牌 GLP-1 药物，FDA 直指其报告流程存在多处漏洞，且整改措施未达要求。检查结束当天，FDA 就向诺和诺德出具了Form 483 表格，清晰列出了其在药品副作用监测和报告环节的多项不合规问题。另外，诺和诺德对不良事件的医学审核周期过长，审核效率低下。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311125239a46036e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311125239a46036e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4144","IE00BKVL7J92.USD","NVOH","NVOX","LU1093756168.USD","NVO","BK4532","BK4590","LU1093756325.SGD","LU0154236417.USD","BK4588","IE00BZ1G4Q59.USD","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618963769","title":"诺和诺德旗下“问题”工厂，又一家药企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618963769?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","NVOX","LU1093756325.SGD","LU0154236417.USD","BK4599","LU1093756168.USD","BK4007","NVOH","NVO","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618968766","title":"诺和诺德(NVO)股票3月10日盘中下跌3.13%：原因全解读","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968766","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618968766?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 02:16","pubTimestamp":1773166595,"startTime":"0","endTime":"0","summary":"• FDA就药品不良反应报告违规行为发出警告信。\n• 由于对研发管线和竞争局势的担忧，分析师下调了诺和诺德的评级。\n• 该公司2026财年指引预计销售额和利润将出现下滑。","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/stocks/261666341-market-movers-nvo-20260310","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","NVOX","LU1093756325.SGD","LU0154236417.USD","NVO","NVOH","BK4532","IE00BKVL7J92.USD","BK7104","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618954420","title":"美股异动丨诺和诺德跌3.3%，因未报告旗下减肥药的所有疑似副作用接获FDA警告信","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954420","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618954420?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 23:33","pubTimestamp":1773156833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1093756168.USD","BK4588","BK4007","BK4599","LU0154236417.USD","BK4585","NVOH","NVOX","BK4532","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618895342","title":"Hims & Hers与诺和诺德达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618895342?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","BK4007","IE00BZ1G4Q59.USD","NVOH","HIMS","LU1093756168.USD","NVOX","BK4532","BK4599","IE00BKVL7J92.USD","LU1093756325.SGD","LU0154236417.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618933958","title":"跨国药企2025年成绩单：“药王”易主，创新资产交易创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2618933958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618933958?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 17:04","pubTimestamp":1773133472,"startTime":"0","endTime":"0","summary":"随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增速，实现651.79亿美元的全年营收，成为增速最快的头部药企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667509930.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667509930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK","CDE","SG9999014575.USD","BK4550","LU1223082519.USD","IE00BN8TJ469.HKD","BK4585","LU2361044865.SGD","LU0130517989.USD","IE00BLSP4452.SGD","IE00BKVL7J92.USD","GSK.UK","LU0868494617.USD","BK4588","IE00B1BXHZ80.USD","MRK","LU1057294990.SGD","BK4534","LU0289739699.SGD","LU2360032135.SGD","LU1291159041.SGD","LU0266013472.USD","NVO","NVOX","LU1023059063.AUD","LU1093756325.SGD","LU0098860793.USD","GSKH","LU1934455863.HKD","LU1989772840.SGD","LU2125154778.USD","LU1571399168.USD","LU0477156953.USD","SG9999014542.SGD","SGXZ57979304.SGD","LU0648001328.SGD","LU1066051225.USD","LU1066051811.HKD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU2361045086.USD","LU1983299246.USD","NVOH","BK4559","01477","BK4516","LU0320765489.SGD","LU2324357040.USD","LU0203347892.USD","SG9999015358.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2618217938","title":"Hims & Hers Health盘前续涨超2%，诺和诺德旗下明星减肥药将登陆平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2618217938","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618217938?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 16:41","pubTimestamp":1773132060,"startTime":"0","endTime":"0","summary":"3月10日消息，美国互联网医疗公司Hims & Hers Health周一股价暴涨超40%，10日盘前续涨2.3%，报22.67美元。原因是诺和诺德宣布将通过Hims平台向美国消费者销售旗下明星减肥药，包括Ozempic和Wegovy注射剂及Wegovy口服片剂，并同步撤回上月提起的专利侵权诉讼。根据双方达成的协议，Hims平台将以诺和诺德自付价格提供这些药物。值得一提的是，诺和诺德此前已将减肥药月费从约1000美元大幅下调至149至299美元区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031016431197abcc6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031016431197abcc6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOX","BK4588","BK4007","HIMZ","BK4532","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","NVOH","HIYY","IE00BKVL7J92.USD","HIMY","HMYY","LU1093756325.SGD","BK4196","BK4599","LU0154236417.USD","HIMS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}